A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a ...

For patients who underwent radical cystectomy for bladder cancer, those with lower net worth incurred higher costs ...

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making ...

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of ...

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and ...

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced ...

Dr. Schiller will discuss the key factors that make the transplant ineligible BPDCN patient population more difficult to ...

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment ...

Lucia Masarova, MD, PhD, discusses some of the latest updates across myeloproliferative neoplasms. Lucia Masarova, MD, PhD, ...

The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end ...

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access ...